The texicology of cannabis and cannabis prohibition

Chemistry and Biodiversity

Volumn 4, Issue 8, 2007, Pages 1744-1769

  Grotenhermen, Franjo ^a  

^a Nova Institut   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BENZODIAZEPINE DERIVATIVE; CANNABIDIOL; CANNABIGEROL; CANNABINOL; CANNABIS; DRONABINOL; NABILONE; PLACEBO; PLANT EXTRACT; TETRAHYDROCANNABINOL CANNABIDIOL COMBINATION; TETRAHYDROCANNABINOL-CANNABIDIOL COMBINATION; UNCLASSIFIED DRUG;

ABSTINENCE; ACCIDENT; ACUTE TOXICITY; ANXIETY; ATAXIA; ATTENTION DISTURBANCE; BLADDER DISEASE; BLOOD PRESSURE; BRADYCARDIA; CANNABIS ADDICTION; CHRONIC PAIN; CIRCULATION; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONCENTRATION LOSS; CONFUSION; COORDINATION DISORDER; COUGHING; DECUBITUS; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DISORIENTATION; DISSOCIATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG USE; DRUNKENNESS; DYSGEUSIA; ENDOCRINE SYSTEM; EUPHORIA; FALLING; FANTASY; FATIGUE; FEAR; FERTILITY; FETUS DEVELOPMENT; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART INFARCTION; HEART RATE; HUMAN; HYPOSALIVATION; INCREASED APPETITE; INFECTION; LETHARGY; MEMORY DISORDER; MOOD DISORDER; MOUTH PAIN; MOUTH ULCER; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE STIFFNESS; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; ORTHOSTATIC HYPOTENSION; OXYGEN CONSUMPTION; PAIN; PANIC; PARESTHESIA; PERCEPTION DISORDER; PHARYNGITIS; PREGNANCY; PRENATAL DRUG EXPOSURE; PREVALENCE; PSYCHOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SLEEP DISORDER; SMOKING; SOMNOLENCE; SYNCOPE; TACHYCARDIA; TEAR FLOW; THIRST; TOXICOLOGY; TREMOR; VISUAL DISORDER; VOMITING; WALKING DIFFICULTY; WEAKNESS; XEROSTOMIA; ANIMAL; DRUG EFFECT; DRUG LEGISLATION; PSYCHOMOTOR PERFORMANCE; RISK ASSESSMENT;

CANNABIS; NICOTIANA TABACUM;

ANIMALS; BLOOD PRESSURE; CANNABIS; COGNITION; HEART RATE; HUMANS; LEGISLATION, DRUG; MARIJUANA ABUSE; PLANT EXTRACTS; PSYCHOMOTOR PERFORMANCE; RISK ASSESSMENT;

EID: 34548498839     PISSN: 16121872     EISSN: 16121880     Source Type: Journal    
DOI: 10.1002/cbdv.200790151     Document Type: Review

References (189)

1. W. Hall, L. Degenhardt, Can. J. Psychiat. 2006, 51, 566.
2. H. Kalant, Prog. Neuropsychopharmacol. Biol. Psychiat. 2004, 28, 849.
3. F. Grotenhermen, Am. J. Drug Delivery 2004, 2, 229.
4. C. L. Hart, A. S. Ward, M. Haney, S. D. Comer, R. W. Foltin, M. W. Fischman, Psychopharmacology (Berlin) 2002, 164, 407.
5. S. R. Wachtel, M. A. ElSohly, S. A. Ross, J. Ambre, H. de Wit, Psychopharmacology (Berlin) 2002, 161, 331.
6. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, A. Thompson, Lancet 2003, 362, 1517.
7. J. P. Zajicek, H. P. Sanders, D. E. Wright, P. J. Vickery, W. M. Ingram, S. M. Reilly, A. J. Nunn, L. J. Teare, P. J. Fox, A. J. Thompson, J. Neurol. Neurosurg. Psychiat. 2005, 76, 1664.
8. R. E. Musty, I. Rossi, J. Cannabis Ther. 2001, 1, 29.
9. P. F. Smith, Curr. Opin. Invest. Drugs 2004, 5, 727.
10. M. R. Tramer, D. Carroll, F. A. Campbell, D. J. Reynolds, R. A. Moore, H. J. McQuay, Br. Med. J. 2001, 323, 16.
11. J. E. Joy, S. J. Watson, J. A. Benson, Eds., 'Marijuana and medicine: Assessing the science base', Institute of Medicine, National Academy Press, Washington DC, 1999.
12. G. R. Thompson, H. Rosenkrantz, U. H. Schaeppi, M. C. Braude, Toxicol. Appl. Pharmacol. 1973, 25, 363.
13. D. T. Wade, P. Makela, P. Robson, H. House, C. Bateman, Mult. Scler. 2004, 10, 434.
14. U. Hagenbach, S. Luz, N. Ghafoor, J. M. Berger, F. Grotenhermen, R. Brenneisen, M. Mäder, Spinal Cord 2007, doi: 10.1038/ sj.sc.3101982.
15. M. Bowman, R. O. Phil, Psychopharmacologia 1973, 29, 159.
16. M. E. Abood, B. R. Martin, Pharmacol. Sci. 1992, 13, 201.
17. L. E. Hollister, Pharmacol. Rev. 1986, 38, 1.
18. R. M. Julien, 'A primer of drug action', W. H. Freeman, New York, 1998.
19. J. A. Halikas, in 'Marijuana: Effects on Human Behavior', Ed. L. L. Miller, Academic Press, New York, 1974.
20. B. Bron, 'Drogenabhängigkeit und Psychose', Springer-Verlag, Berlin, Heidelberg, New York, 1982.
21. F. M. Leweke, U. Schneider, M. Thies, T. F. Münte, H. M. Emrich, Psychopharmacology (Berlin) 1999, 142, 230.
22. H. Thomas, Br. J. Psychiat. 1993, 163, 141.
23. W. Hall, L. Degenhardt, Aust. N. Z. J. Psychiat. 2000, 34, 26.
24. A. Johns, Br. J. Psychiat. 2001, 178, 116.
25. M. E. Meyer, in 'Marijuana and health hazards: Methodologic issues in current Research', Ed. J. R. Tinklenberg, Academic Press, New York, 1975.
26. F. M. Leweke, C. Kampmann, M. Radwan, D. E. Dietrich, S. Johannes, H. M. Emrich, T. F. Münte, Neuropsychobiology 1998, 37, 104.
27. H. Moskowitz, S. Sharma, W. McGlothlin, Percept. Mot. Skills 1972, 35, 875.
28. L. D. Chait, J. Pierri, Addict. Behav. 1989, 14, 61.
29. A. S. Carlin, C. B. Bakker, L. Halpern, R. D. Post, J. Abnorm. Psychol. 1972, 80, 132.
30. R. T. Jones, G. C. Stone, Psychopharmacologia 1970, 18, 108.
31. M. Earleywine, 'Understanding Marijuana: A New Look at the Scientific Evidence', Oxford University Press, USA, 2005.
32. C. L. Hart, W. van Gorp, M. Haney, R. W. Foltin, M. W. Fischman, Neuropsychopharmacology 2001, 25, 757.
33. F. R. Freemon, Psychopharmacologia 1974, 35, 39.
34. S. C. Clark, C. Greene, G. W. Karr, K. L. Maccannell, S. L. Milstein, Can. J. Physiol. Pharmacol. 1974, 52, 706.
35. R. T. Jones, N. Benowitz, R. I. Herning, J. Clin. Pharmacol. 1981, 21, 143.
36. L. Bachs, H. Morland, Forensic Sci. Int. 2001, 124, 200.
37. M. A. Mittleman, R. A. Lewis, M. Maclure, J. B. Sherwood, J. E. Muller, Circulation 2001, 103, 2805.
38. J. P. Prestifilippo, J. Fernandez-Solari, C. de la Cal, M. Iribarne, A. M. Suburo, V. Rettori, S. M. McCann, J. C. Elverdin, Exp. Biol. Med. (Maywood) 2006, 231, 1421.
39. L. E. Hollister, J. Psychoact. Drugs 1988, 20, 3.
40. E. A. Formukong, A. T. Evans, F. J. Evans, J. Pharm. Pharmacol. 1989, 41, 705.
41. E. Deusch, H. G. Kress, B. Kraft, S. A. Kozek-Langenecker, Anesth. Analg. 2004, 99, 1127, table of contents.
42. Sativex product monograph, http://www.bayerhealth.ca/ display.cfm?Object_ID=272&Article_ID=121&expandMenu_ID= 53&prevSubItem=5_52.
43. K. R. Müller-Vahl, U. Schneider, H. M. Emrich, Movement Disord. 1999, 14, 1038.
44. T. Esfandyari, M. Camilleri, I. Ferber, D. Burton, K. Baxter, A. R. Zinsmeister, Neurogastroenterol. Motil. 2006, 18, 831.
45. J. E. Shook, T. F. Burks, J. Pharmacol. Exp. Ther. 1989, 249, 444.
46. Marinol prescribing information, http://www.marinol.com/images/ pdf/MARINOLPI.pdf.
47. R. K. Jones, D. Shinar, J. M. Walsh, 'State of knowledge of drug impaired driving', Final report, National Highway Traffic Safety Administration Report DOT HS 809 642, 2003.
48. R. Tunbridge, A. Clark, B. N. Ward, L. Dye, G. Berghaus, 'Prioritising drugs and medicines for development of roadside impairment testing', Project Deliverable DR1, CERTIFIED EU Research Project (Contract No. RO-98-3054), School of Psychology, University of Leeds, 2000.
49. I. Kurzthaler, T. Bodner, G. Kemmler, T. Entner, J. Wissel, T. Berger, W. W. Fleischhacker, Hum. Psychopharmacol. 2005, 20, 291.
50. K. R. Müller-Vahl, H. Prevedel, K. Theloe, H. Kolbe, H. M. Emrich, U. Schneider, Neuropsychopharmacology 2003, 28, 384.
51. S. R. Lowenstein, J. Koziol-McLain, J. Trauma 2001, 50, 313.
52. F. Grotenhermen, G. Leson, G. Berghaus, O. Drummer, H. P. Krüger, M. Longo, H. Moskowitz, B. Perrine, J. Ramaekers, A. Smiley, R. Tunbridge, 'Developing science-based per se limits for driving under the influence of cannabis (DUIC). Findings and recommendations by an expert panel', nova-Institut, Hürth (Germany), 2005.
53. O. H. Drummer, J. Gerostamoulos, H. Batziris, M. Chu, J. Caplehorn, M. D. Robertson, P. Swann, Accid. Anal. Prev. 2004, 36, 239.
54. B. Laumon, B. Gadegbeku, J. L. Martin, M. B. Biecheler, Br. Med. J. 2005, 331, 1371.
55. A. Wright, P. Terry, Psychopharmacology 2002, 160, 213.
56. A. M. Smiley, in 'The health effects of cannabis', Eds. H. Kalant, W. Corrigal, W. Hall, R. Smart, Addiction Research Foundation, Toronto, 1999, p. 173.
57. K. W. Terhune, 'The role of alcohol, marijuana and other drugs in the accidents of injured drivers', Technical Report to US Department of Transportation, Calspan Field Services, Inc., 1982.
58. A. F. Williams, M. A. Peat, D. J. Crouch, J. K. Wells, B. S. Finkle, Public Health Rep. 1985, 100, 19.
59. K. W. Terhune, C. A. Ippolito, D. L. Hendricks, J. G. Michalovic, S. C. Bogema, P. Santinga, R. Blomberg, D. F. Preusser, 'The incidence and role of drugs in fatally injured drivers', DOT HS 808 065, National Highway Safety Administration, 1992.
60. O. H. Drummer, 'Drugs in drivers killed in Australian road traffic accidents. The use of responsibility analysis to investigate the contribution of drugs to fatal accidents. Report No. 0594', Victorian Institute of Forensic Pathology, Department of Forensic Medicine, Monash University, 1994.
61. M. C. Longo, C. E. Hunter, R. J. Lokan, J. M. White, M. A. White, Accid. Anal. Prev. 2000, 32, 623.
62. O. Drummer, Victorian Institute of Forensic Medicine, Department of Forensic Medicine, Monash University, Victoria, Australia, personal communication, April 2004.
63. D. Vinson, Missouri Med. 2006, 103.
64. S. G. Gerberich, S. Sidney, B. L. Braun, J. S. Tekawa, K. K. Tolan, C. P. Quesenberry, Ann. Epidemiol. 2003, 13, 230.
65. P. C. Chan, R. C. Sills, A. G. Braun, J. K. Haseman, J. R. Bucher, Fundam. Appl. Toxicol. 1996, 30, 109.
66. S. Sidney, J. E. Beck, I. S. Tekawa, C. P. Quesenberry, G. D. Friedman, Am. J. Public Health 1997, 87, 585.
67. House of Lords Select Committee on Science and Technology, 'Cannabis. The scientific and medical evidence', The Stationery Office, London, 1998.
68. E. Russo, M. L. Mathre, A. Byrne, R. Velin, P. J. Bach, J. Sanchez-Ramos, K. A. Kirlin, J. Cannabis Ther. 2002, 2, 3.
69. M. A. ElSohly, in 'Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential', Eds. F. Grotenhermen, E. Russo, Haworth Press, Binghamton NY, 2002, p. 27.
70. J. McPartland, in 'Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential', Eds. F. Grotenhermen, E. Russo, Haworth Press, Binghamton NY, 2002, p. 337.
71. British Medical Association, 'Therapeutic uses of cannabis', Harwood Academic Publishers, Amsterdam, 1997.
72. M. D. Roth, A. Arora, S. H. Barsky, E. C. Kleerup, M. Simmons, D. P. Tashkin, Am. J. Respir. Crit. Care Med. 1998, 157, 928.
73. D. R. Taylor, R. Poulton, T. E. Moffitt, P. Ramankutty, M. R. Sears, Addiction 2000, 95, 1669.
74. D. P. Tashkin, A. H. Coulson, V. A. Clark, M. Simmons, L. B. Bourque, S. Duann, G. H. Spivey, H. Gong, Am. Rev. Respir. Dis. 1987, 135, 209.
75. S. H. Barsky, M. D. Roth, E. C. Kleerup, M. Simmons, D. P. Tashkin, J. Nat. Cancer Inst. 1998, 90, 1198.
76. S. E. Fligiel, M. D. Roth, E. C. Kleerup, S. H. Barsky, M. S. Simmons, D. P. Tashkin, Chest 1997, 112, 319.
77. M. Hashibe, K. Straif, D. P. Tashkin, H. Morgenstern, S. Greenland, Z. F. Zhang, Alcohol 2005, 35, 265.
78. M. Hashibe, H. Morgenstem, Y. Cui, D. P. Tashkin, Z. F. Zhang, W. Cozen, T. M. Mack, S. Greenland, Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1829.
79. A. Giuffrida, F. M. Leweke, C. W. Gerth, D. Schreiber, D. Koethe, J. Faulhaber, J. Klosterkotter, D. Piomelli, Neuropsychopharmacology 2004, 29, 2108.
80. L. Arseneault, M. Cannon, R. Poulton, R. Murray, A. Caspi, T. E. Moffitt, Br. Med. J. 2002, 325, 1212.
81. R. F. Ferdinand, F. Sondeijker, J. van der Ende, J. P. Selten, A. Huizink, F. C. Verhulst, Addiction 2005, 100, 612.
82. D. M. Fergusson, L. J. Horwood, A. L. Beautrais, Addiction 2003, 98, 1681.
83. C. Henquet, L. Krabbendam, J. Spauwen, C. Kaplan, R. Lieb, H. U. Wittchen, J. van Os, Br. Med. J. 2005, 330, 11.
84. N. C. Stefanis, P. Delespaul, C. Henquet, C. Bakoula, C. N. Stefanis, J. van Os, Addiction 2004, 99, 1333.
85. J. van Os, M. Bak, M. Hanssen, R. V. Bijl, R. de Graaf, H. Verdoux, Am. J. Epidemiol. 2002, 156, 319.
86. S. Zammit, P. Allebeck, S. Andreasson, I. Lundberg, G. Lewis, Br. Med. J. 2002, 325, 1199.
87. L. Arseneault, M. Cannon, J. Witton, R. M. Murray, Br. J. Psychiat. 2004, 184, 110.
88. L. Degenhardt, W. Hall, Can. J. Psychiat. 2006, 51, 556.
89. M. Weiser, S. Noy, Dialogues Clin. Neurosci. 2005, 7, 81.
90. J. de Irala, M. Ruiz-Canela, M. A. Martinez-Gonzalez, Med. Sci. Monit. 2005, 11, RA355.
91. S. Kumra, J. Wu, K. Cervellione, J. Kane, P. Szesko, 'The Impact of Recurrent Exposure to Cannabis on Brain Development in Adolescents with Schizophrenia and Healthy Volunteers', Abstract presented at the 2005 Meeting of the Radiological Society of North America, Chicago, 27 November-2 December, 2005.
92. L. E. Delisi, H. C. Bertisch, K. Brown, M. Majcher, A. Bappal, K. U. Szulc, B. A. Ardekani, Harm. Reduct. J. 2006, 3, 17.
93. L. J. Phillips, C. Curry, A. R. Yung, H. P. Yuen, S. Adlard, P. D. McGorry, Aust. N. Z. J. Psychiat. 2002, 36, 800.
94. H. C. Margolese, J. Carlos Negrete, R. Tempier, K. Gill, Schizophr. Res. 2006, 83, 65.
95. L. Degenhardt, W. Hall, M. Lynskey, Addiction 2001, 96, 1603.
96. W. Swift, P. Gates, P. Dillon, Harm. Reduct. J. 2005, 2, 18.
97. J. Howard, K. A. Anie, A. Holdcroft, S. Korn, S. C. Davies. Br. J. Haematol. 2005, 131, 123.
98. J. E. Beal, R. Olson, L. Laubenstein, J. O. Morales, P. Bellman, B. Yangco, L. Lefkowitz, T. F. Plasse, K. V. Shepard, J. Pain Symptom Manage. 1995, 10, 89.
99. W. Regelson, J. R. Butler, J. Schulz, T. Kirk, L. Peek, M. L. Green, M. O. Zalis, in 'Pharmacology of marihuana', Ed. M. C. Braude, S. Szara, Raven Press, New York, 1976, Vol 2, p. 763.
100. G. Gobbi, F. R. Bambico, R. Mangieri, M. Bortolato, P. Campolongo, M. Solinas, T. Cassano, M. G. Morgese, G. Debonnel, A. Duranti, A. Tontini, G. Tarzia, M. Mor, V. Trezza, S. R. Goldberg, V. Cuomo, D. Piomelli, Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 18620.
101. S. Gaetani, V. Cuomo, D. Piomelli, Trends Mol. Med. 2003, 9, 474.
102. S. Patel, C. T. Roelke, D. J. Rademacher, W. E. Cullinan, C. J. Hillard, Endocrinology 2004, 145, 5431.
103. J. Macleod, R. Oakes, A. Copello, I. Crome, M. Egger, M. Hickman, T. Oppenkowski, H. Stokes-Lampard, G. Davey Smith, Lancet 2004, 363, 1579.
104. D. W. Brook, J. S. Brook, C. Zhang, P. Cohen, M. Whiteman, Gen. Psychiat. 2002, 59, 1039.
105. R. McGee, S. Williams, R. Poulton, T. Moffitt, Addiction 2000, 95, 491.
106. D. M. Fergusson, L. J. Horwood, N. Swain-Campbell, Addiction 2002, 97, 1123.
107. R. E. Musty, L. Kaback, Life Sci. 1995, 56, 2151.
108. V. S. Harder, A. R. Morral, J. Arkes, Addiction 2006, 101, 1463.
109. C. Y. Chen, F. A. Wagner, J. C. Anthony, Soc. Psychiat. Psychiat. Epidemiol. 2002, 37, 199.
110. B. E. Green, C. Ritter, J. Health Soc. Behav. 2000, 41, 40.
111. M. T. Lynskey, A. L. Glowinski, A. A. Todorov, K. K. Bucholz, P. A. Madden, E. C. Nelson, D. J. Statham, N. G. Martin, A. C. Heath, Arch. Gen. Psychiat. 2004, 61, 1026.
112. R. I. Herning, W. E. Better, K. Tate, J. L. Cadet, Neurology 2005, 64, 488.
113. W. Jiang, Y. Zhang, L. Xiao, J. Van Cleemput, S. P. Ji, G. Bai, X. Zhang, J. Clin. Invest. 2005, 115, 3104.
114. A. Bilkei-Gorzo, I. Racz, O. Valverde, M. Otto, K. Michel, M. Sarstre, A. Zimmer, Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 15670.
115. I. Grant, R. Gonzalez, C. L. Carey, L. Natarajan, T. Wolfson, J. Int. Neuropsychol. Soc. 2003, 9, 679.
116. H. G. Pope, A. J. Gruber, D. Yurgelun-Todd, Curr. Psychiat. Rep. 2001, 3, 507.
117. K. I. Bolla, K. Brown, D. Eldreth, K. Tate, J. L. Cadet, Neurology 2002, 59, 1337.
118. G. Jager, R. S. Kahn, W. Van Den Brink, J. M. Van Ree, N. F. Ramsey, Psychopharmacology 2006, 185, 358.
119. H. G. Pope, A. J. Gruber, J. I. Hudson, G. Cohane, M. A. Huestis, D. Yurgelun-Todd, Drug Alcohol Depend. 2003, 69, 303.
120. R. T. Jones, N. Benowitz, in 'The Pharmacology of Marihuana', Eds. M. C. Braude, S. Szara, Raven Press, New York, 1976, Vol. 2, p. 627.
121. R. T. Jones, N. Benowitz, J. Bachman, Ann. N.Y. Acad. Sci. 1976, 282, 221.
122. N. L. Benowitz, R. T. Jones, Clin. Pharmacol. Ther. 1975, 18, 287.
123. D. T. Wade, P. M. Makela, H. House, C. Bateman, P. Robson, Mult. Scler. 2006, 12, 639.
124. M. Maurer, V. Henn, A. Dittrich, A. Hofmann, Eur. Arch. Psychiat. Clin. Neurosci. 1990, 240, 1.
125. J. E. Beal, R. Olson, L. Lefkowitz, L. Laubenstein, P. Bellman, B. Yangco, J. O. Morales, R. Murphy, W. Powderly, T. F. Plasse, K. W. Mosdell, K. V. Shepard, J. Pain Symptom Manage. 1997 14, 7.
126. A. J. Budney, J. R. Hughes, B. A. Moore, R. Vandrey, Am. J. Psychiat. 2004, 161, 1967.
127. M. Haney, A. S. Ward, S. D. Comer, R. W. Foltin, M. W. Fischman, Psychopharmacology (Berlin) 1999, 141, 385.
128. A. J. Budney, B. A. Moore, R. G. Vandrey, J. R. Hughes, J. Abnorm. Psychol. 2003, 112, 393.
129. J. C. Anthony, L. A. Warner, R. C. Kessler, Exp. Clin. Psychopharmacol. 1994, 2, 244.
130. A. Perkonigg, R. Lieb, M. Hofler, P. Schuster, H. Sonntag, H. U. Wittchen, Addiction 1999, 94, 1663.
131. W. Swift, W. Hall, M. Teesson, Addiction 2001, 96, 737.
132. K. von Sydow, R. Lieb, H. Pfister, M. Hofler, H. Sonntag, H. U. Wittchen, Drug Alcohol Depend. 2001, 64, 347.
133. W. Swift, W. Hall, J. Copeland, Drug Alcohol Depend. 2000, 59, 309.
134. M. T. Lynskey, A. C. Heath, E. C. Nelson, K. K. Bucholz, P. A. Madden, W. S. Slutske, D. J. Statham, N. G. Martin, Psychol. Med. 2002, 32, 195.
135. J. Taylor, S. Malone, W. G. Iacono, M. McGue, J. Am. Acad. Child Adolesc. Psychiat. 2002, 41, 386.
136. K. Chen, D. B. Kandel, M. Davies, Drug Alcohol Depend. 1997, 46, 53.
137. L. Degenhardt, W. Hall, Nicotine Tob. Res. 2001, 3, 225.
138. L. Murphy, in 'Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential', Eds. F. Grotenhermen, E. Russo, Haworth Press, Binghamton NY, 2002, p. 289.
139. W. C. Hembree, G. G. Nahas, P. Zeidenberg, H. F. Huang, Adv. Biosci. 1978, 22, 429.
140. M. C. Chang, D. Berkery, R. Schuel, S. G. Laychock, A. M. Zimmerman, S. Zimmerman, H. Schuel, Mol. Reprod. Dev. 1993, 36, 507.
141. J. H. Mendelson, N. K. Mello, NIDA. Res. Monogr. 1984, 44, 97.
142. R. I. Block, R. Farinpour, J. A. Schlechte, Drug Alcohol Depend. 1991, 28, 121.
143. J. H. Mendelson, N. K. Mello, J. Ellingboe, A. S. Skupny, B. W. Lex, M. Griffin, J. Pharmacol. Exp. Ther. 1986, 237, 862.
144. J. H. Mendelson, N. K. Mello, J. Ellingboe, J. Pharmacol. Exp. Ther. 1985, 232, 220.
145. G. S. Chopra, B. S. Jandu, Ann. N.Y. Acad. Sci. 1976, 282, 95.
146. B. A. Mueller, J. R. Daling, N. S. Weiss, D. E. Moore, Epidemiology 1990, 1, 195.
147. M. R. Joesoef V. Beral, S. O. Aral, R. T. Rolfs, D. W. Cramer, Ann. Epidemiol. 1993, 3, 592.
148. F. Grotenhermen, G. Leson, P. Pless, 'Assessment of exposure to and human health risk from THC and other cannabinoids in hemp foods', Leson Environmental Consulting, Berkeley, 2001.
149. L. E. Hollister, F. Moore, S. Kanter, E. Noble, Psychopharmacologia 1970, 17, 354.
150. E. J. Cone, R. E. Johnson, J. D. Moore, J. D. Roache, Pharmacol. Biochem. Behav. 1986, 24, 1749.
151. E. K. Cruickshank, Ann. N.Y. Acad. Sci. 1976, 282, 162.
152. M. A. Permutt, D. W. Goodwin, R. Schwin, S. Y. Hill, Am. J. Psychiat. 1976, 133, 220.
153. L. E. Hollister, G. M. Reaven, Clin. Pharmacol. Ther. 1974, 16, 297.
154. O. M. Habayeb, A. H. Taylor, M. D. Evans, M. S. Cooke, D. J. Taylor, S. C. Bell, J. C. Konje, J. Clin. Endocrinol. Metab. 2004, 89, 5482.
155. P. A. Fried, B. Watkinson, R. Gray, Neurotoxicol. Teratol. 1998, 20, 293.
156. H. Wang, H. Xie, Y. Guo, H. Zhang, T. Takahashi, P. J. Kingsley, L. J. Marnett, S. K. Das, B. F. Cravatt, S. K. Dey, J. Clin. Invest. 2006, 116, 2122.
157. D. E. Hutchings, B. R. Martin, Z. Gamagaris, N. Miller, T. Fico, Life. Sci. 1989, 44, 697.
158. P. A. Fried, B. Watkinson, R. Gray, Neurotoxicol. Teratol. 2003, 25, 427.
159. G. A. Richardson, C. Ryan, J. Willford, N. L. Day, L. Goldschmidt, Neurotoxicol. Teratol. 2002, 24, 309.
160. S. W. Jacobson, L. M. Chiodo, R. J. Sokol, J. L. Jacobson, Pediatrics 2002, 109, 815.
161. T. W. Klein, C. Newton, H. Friedman, Adv. Exp. Med. Biol. 1998, 437, 215.
162. R. Pacifici, P. Zuccaro, S. Pichini, P. N. Roset, S. Poudevida, M. Farre, J. Segura, R. De la Torre, J. Am. Med. Assoc. 2003, 289, 1929.
163. S. Katona, E. Kaminski, H. Sanders, J. Zajicek, Clin. Exp. Immunol. 2005, 140, 580.
164. R. A. Kaslow, W. C. Blackwelder, D. G. Ostrow, D. Yerg, J. Palenicek, A. H. Coulson, R. O. Valdiserri, J. Am. Med. Assoc. 1989, 261, 3424.
165. M. J. Di Franco, H. W. Shephard, D. J. Hunter, T. D. Tosteson, M. S. Ascher, Ann. Epidemiol. 1996, 6, 283.
166. B. M. Bredt, D. Higuera-Alhino, S. B. Shade, S. J. Hebert, J. M. McCune, D. I. Abrams, J. Clin. Pharmacol. 2002, 42, 82S.
167. B. Tindall, C. R. Philpot, D. A. Cooper, J. Gold, B. Donovan, R. Penny, T. Barnes, Aust. N. Z. J. Med. 1988, 18, 8.
168. R. M. Whitfield, L. M. Bechtel, G. H. Stanch, Alcohol Clin. Exp. Res. 1997, 21, 122.
169. N. Rodondi, M. J. Pletcher, K. Liu, S. B. Hulley, S. Sidney, Am. J. Cardiol. 2006, 98, 478.
170. M. Warren, K. Frost-Pineda, M. Gold, J. Addict. Dis. 2005, 24, 95.
171. S. Steffens, N. R. Veillard, C. Arnaud, G. Pelli, F. Burger, C. Staub, M. Karsak, A. Zimmer, J. L. Frossard, F. Mach. Nature 2005, 434, 782.
172. P. Combemale, T. Consort, L. Denis-Thelis, J. L. Estival, M. Dupin, J. Kanitakis, Br. J. Dermatol. 2005, 152, 166.
173. C. Hezode, F. Roudot-Thoraval, S. Nguyen, P. Grenard, B. Julien, E. S. Zafrani, J. M. Pawlotsky, D. Dhumeaux, S. Lotersztajn, A. Mallat, Hepatology 2005, 42, 63.
174. D. L. Sylvestre, B. J. Clements, Y. Malibu, Eur. J. Gastroenterol. Hepatol. 2006, 18, 1057.
175. R. R. Edwards, M. T. Smith, I. Kudel, J. Haythornthwaite, Pain 2006, 126, 272.
176. G. D. Lundberg, Medscape Gen. Med. 2005, 7, 47.
177. O. Lawrence, J. D. Gostin, J. Am. Med. Assoc. 2005, 294, 842.
178. J. Hoey, Can. Med. Assoc. J. 2001, 164, 1397.
179. C. H. Ashton, Br. J. Anaesth. 1999, 83, 637.
180. L. Böllinger, S. Quensel, J. Drug Issues 2002, 32, 553.
181. J. A. Miron, 'The budgetary implications of marijuana prohibition', Marijuana Policy Project, Washington D. C., 2005; http://www.prohibitioncosts.org.
182. Commission on Narcotic Drugs of the United Nations, press release, 17 April 2003; http://www.unodc.org/unodc/press_release_2003-04-17_5.html.
183. A. Joffe, S. Yancy, and the Committee on Substance Abuse and Committee on Adolescence, Pediatrics 2004, 113, 632.
184. R. MacCoun, P. Reuter, Br. J. Psychiat. 2001, 178, 123.
185. European Monitoring Centre for Drugs and Drug Addiction, Annual report 2006, http://ar2006.emcdda.europa.eu/en/home-en.html.
186. E. Single, P. Christie, R. Ali, J. Public Health Policy 2000, 21, 157.
187. C. Reinarman, P. D. Cohen, H. L. Kaal, Am. J. Public Health 2004, 94, 836.
188. P. McArdle, A. Wiegersma, E. Gilvarry, B. Kolte, S. McCarthy, M. Fitzgerald, A. Brinkley, M. Blom, I. Stoeckel, A. Pierolini, I. Michels, R. Johnson, S. Quensel, Addiction 2002, 97, 329.
189. A. E. Kokkevi, A. A. Arapaki, C. Richardson, S. Florescu, M. Kuzman, E. Stergar, Drug Alcohol Depend. 2007, 88, 308.